Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
This study has been completed.
Study NCT00070590   Information provided by Actelion
First Received: October 6, 2003   Last Updated: January 29, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Fibrosis
Scleroderma, Systemic
Additional conditions recognized in this trial
Fibrosis
Lung Diseases, Interstitial
More general conditions related to this trial
Connective Tissue Diseases
Lung Diseases
Pathologic Processes
Respiratory Tract Diseases
Skin Diseases
Interventions listed in this trial
Bosentan
More general drug interventions related to this trial
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Actelion


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services